Key result
SARS-CoV-2 infection linked to ~124% higher risk of major thrombotic events in CAD patients.
Why the study?
This study evaluated the thrombotic risk associated with SARS-CoV-2 infection among hospitalized patients with angiographically confirmed CAD.
Does SARS-CoV-2 infection increase the risk of major thrombotic events in patients with coronary artery disease?
Cohort (n=4,183)
No
Does SARS-CoV-2 infection increase the risk of major thrombotic events in patients with coronary artery disease?
Hazard Ratio: 2.24 (95% CI 1.67–3)
Absolute Event Rate: 7.27% vs 3.75%
p-value: p=<0.001
SARS-CoV-2 infection significantly increases the short- to mid-term risk of major thrombotic events in patients with pre-existing coronary artery disease, particularly within the first 3 months post-infection.
This study evaluated the thrombotic risk associated with SARS-CoV-2 infection among hospitalized patients with angiographically confirmed coronary artery disease (CAD). A prospective cohort design was used, including 2,078 CAD patients without coronavirus disease 2019 (COVID-19) admitted between January and April 2021 and 2,105 CAD patients with COVID-19 admitted between December 2022 and March 2023. The primary outcome was a composite of major thrombotic events. Patients with COVID-19 showed higher event incidence during 12-month follow-up (7.27% vs. 3.75%), with an adjusted hazard ratio (aHR) of 2.24. The risk was markedly elevated in the first 3 months after infection (hazard ratio [HR] 7.77), then declined but remained above baseline through 12 months. The findings indicate that SARS-CoV-2 infection is associated with a distinct temporal increase in thrombotic vulnerability among CAD patients, highlighting an early period of heightened risk that may inform post-infection monitoring strategies.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) conducted a cohort in Coronary artery disease (CAD) (n=4,183). SARS-CoV-2 infection vs. No SARS-CoV-2 infection was evaluated on Composite of major thrombotic events (cardiovascular death, non-fatal MI, stent thrombosis, unplanned revascularization, ischemic stroke, VTE, and peripheral arterial thrombosis) at 12 months (aHR 2.24, 95% CI 1.67-3.00, p=<0.001). SARS-CoV-2 infection in patients with coronary artery disease was associated with a significantly increased risk of major thrombotic events at 12 months (aHR 2.24), with the highest risk in the first 3 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: